News & Insights

Official updates, press releases, and original thought leadership from the AltrixBio team

News & Press Releases

09/15/2025

AltrixBio Raises $5 Million Series A Financing and Appoints David Pass as CEO to Advance Lead Candidate into the Clinic

Coming Soon:

Past Events:

Event- 01/12 - 1/14/2026 David Pass, CEO, to present at Biotech Showcase in San Francisco View Presentation →

Event- 09/17/2025 David Pass, CEO, to present and attend at Obesity Science and Innovation meeting in Boston

Event- 10/13-30/2025 David Pass, CEO, to present and attend at BioFuture in New York

Media inquiries? Contact our team:

CONTACT US

Thought Leadership

Pre-clinical Publications

LuCI Acute Results

Lee Y, Deelman T, Chen Keyue, Lin Dawn, Tavakkoli Ali, and Karp, Jeffrey. Therapeutic luminal coating of the intestine, Nature Materials, 1018 June 10.1038/s41563-018- 0106-5.

LuCI Chronic Results

Lo T, Lee Y, Tseng CY, Hu Y, Connelly MA, Mantzoros CS, Karp JM, Tavakkoli A. Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism. 2022 Jan;126:154917. doi: 10.1016/j.metabol.2021.154917. Epub 2021 Oct 21. PMID: 34687727; PMCID: PMC8666968.

References

Courcoulas AP, Yanovski SZ, Bonds D, Eggerman TL, Horlick M, Staten MA, Arterburn DE. Long-term outcomes of bariatric surgery: a National Institutes of Health symposium. JAMA Surg. 2014 Dec;149(12):1323-9. doi:10.1001/jamasurg.2014.2440. PMID: 25271405; PMCID: PMC5570469.
Lee Y, Deelman TE, Chen K, Lin DSY, Tavakkoli A, Karp JM. Therapeutic luminal coating of the intestine. Nat Mater. 2018;17(10):957-63. doi:10.1038/s41563-018-0106-5.
Lo T, Lee Y, Tseng C-Y, Hu Y, Connelly MA, Mantzoros CS, Karp JM, Tavakkoli A. Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. Metabolism. 2022;126:154917. doi:10.1016/j.metabol.2021.154917.
Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–12. doi:10.2147/DMSO.S141235
Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report. Atlanta (GA): U.S. Department of Health and Human Services; [cited 2025 Sep 13]
World Health Organization. Obesity and overweight. Geneva: WHO; 2025 May 7 [cited 2025 Sep 5]. Available from:
Heshmati K, Harris DA, Aliakbarian H, Tavakkoli A, Sheu EG. Comparison of early type 2 diabetes improvement after gastric bypass and sleeve gastrectomy: medication cessation at discharge predicts 1-year outcomes. Surg Obes Relat Dis. 2019;15(12):2025–2032. doi:10.1016/j.soard.2019.04.004. Epub 2019 Apr 22. PMID: 31711946.
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–256.e5. doi:10.1016/j.amjmed.2008.09.041
Carlsson LMS, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al. Durability of remission of type 2 diabetes after gastric bypass and sleeve gastrectomy: the Swedish Obese Subjects study. N Engl J Med. 2020;383(15):1443–1453. doi:10.1056/NEJMoa2003297
Saeed L, Sharif G, Eda S, Raju Tullimalli I, Amin A, Riyalat AA, Alrashid FF, Abdelrahim AA. Comparative Effectiveness of Bariatric Metabolic Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Outcomes and Mortality: A Meta-Analysis. Cureus. 2024 Oct 17;16(10):e71684. doi: 10.7759/cureus.71684. PMID: 39552962;
Stenberg E, Cao Y, Ottosson J, Hedberg S, Näslund E. Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes. Diabetes Obes Metab. 2024 Dec;26(12):5812-5818. doi: 10.1111/dom.15952. Epub 2024 Sep 18. PMID: 39295084.